MDVN is in an Uptrend called by SmarTrend on September 13, 2010 at $11.65. With a price of $22.81 at the end of April 2011, this stock has increased 93% since Smar-Trend’s Uptrend was issued. REGN (Regeneron Pharmaceuticals, …
went public with a $9.3 billion offer for cancer drug maker Medivation Inc MDVN.O. Janus was the 10th-biggest investor in Medivation as of the end of the year, according to Thomson Reuters data, and Acker said multiple bidders could be …
Pfizer's big deal: Shares in Medivation (MDVN) are surging by about 20% premarket as Pfizer ... The announcement caused Syngenta stock to surge by about 11% in Europe. State-owned ChemChina announced earlier this year that it …
Outside cancer, Pfizer has had other disappointments; it recently announced that its drug with Medivation (MDVN), Dimebon ... He adds, "Everyone knows the reasons you shouldn't buy Pfizer stock -- the looming patent expirations, …
(Continued from Prior Part) Medivation’s key assets Medivation’s (MDVN) only commercialized drug ... Any events specific to a company, industry, or economy can lead to volatility in a stock’s price. To gain exposure to equity while avoiding …
The biotech industry?s surge in 2013 seems to have cooled in recent weeks as the sector has been hit by a broad …
European and Asian stock markets slid Friday on reinforced concerns about ... whose shares slumped 4.9 percent in afternoon trading after US biotech company Medivation (NasdaqGS: MDVN - news) rejected an unsolicited $9.3 billion …
Today’s stock suggestion is biopharmaceutical company Medivation (MDVN). Continue Reading Below Medivation works in collaboration with drug companies to develop novel therapies for serious diseases. They’re building their success in …